Apple F S, Walker F C, Dietzler D N
Ann Clin Lab Sci. 1983 Sep-Oct;13(5):385-92.
In patients on phenytoin therapy and with renal failure, the enzyme multiplied immunoassay technique (EMIT), unlike gas-liquid chromatographic techniques (GLC), can give falsely elevated serum phenytoin concentrations. In 25 patients (creatinine less than or equal to 1.5 mg per dl), discrepancies between the serum EMIT and GLC phenytoin concentrations were accounted for by the inherent imprecision of the methods. However, in 16 of 18 uremic patients (creatinine greater than or equal to 1.7 mg per dl), the discrepancies were greater than could be accounted for by imprecision. For these 18 patients the correlation (r = 0.49) between the discrepancies and the creatinine concentrations appeared to be statistically significant (P less than 0.05). The linear regression relationship was inadequate for accurate correction of the EMIT values using the creatinine concentrations. Another original observation was that in most cases renal dialysis decreases the EMIT to GLC discrepancy. However, post-dialysis serum samples with a creatinine concentration greater than 1.7 mg per dl usually still showed a falsely elevated EMIT phenytoin concentration.
在接受苯妥英治疗且患有肾衰竭的患者中,与气液色谱技术(GLC)不同,酶倍增免疫分析技术(EMIT)会使血清苯妥英浓度出现假性升高。在25例患者(肌酐小于或等于1.5毫克/分升)中,血清EMIT法和GLC法检测的苯妥英浓度差异是由方法本身的不精确性导致的。然而,在18例尿毒症患者中的16例(肌酐大于或等于1.7毫克/分升),差异大于不精确性所能解释的范围。对于这18例患者,差异与肌酐浓度之间的相关性(r = 0.49)似乎具有统计学意义(P小于0.05)。线性回归关系不足以根据肌酐浓度准确校正EMIT值。另一个原始观察结果是,在大多数情况下,肾脏透析会降低EMIT法与GLC法检测结果的差异。然而,透析后肌酐浓度大于1.7毫克/分升的血清样本通常仍显示EMIT法检测的苯妥英浓度假性升高。